Is medically induced menopause that’s left untreated a malpractice-level miss?
Industry Buzz
This situation just honestly pisses me off so much, and it is actually medical malpractice, what happened to this woman.
—Jordan Emont, MD, MPH
A woman in her early 40s had survived lymphoma, chemotherapy, and a bone marrow transplant. But for the 6 years that followed, she lived with another consequence of treatment: chemotherapy-induced menopause that began in her mid-30s.
She had not had a period since treatment. Her labs had shown markedly elevated FSH and low estradiol. She had what Jordan Emont, MD, MPH, described as “every symptom you can imagine of menopause.”
What she apparently did not have was a clear explanation of what had happened to her body—or a treatment plan.
According to Dr. Emont, the patient had been told at some point that the symptoms might last 10 years, would likely improve, and that there was not much to do. In a recent TikTok video, he called that response “medical malpractice.”
“This situation just honestly pisses me off so much, and it is actually medical malpractice, what happened to this woman,” he said.
The legal threshold for malpractice depends on the facts of a case. But Dr. Emont’s clinical argument was blunt: When medical care causes a patient to enter menopause decades early, clinicians have a responsibility to recognize, explain, and treat it.
This is not typical menopause
The patient’s age is the key detail. This was not menopause at 51, with hormone therapy considered primarily for symptom relief after an individualized risk-benefit discussion. This was menopause in the mid-30s, induced by cancer treatment.
In premature or early menopause, estrogen loss is associated with higher long-term risks, including bone loss, fracture, cardiovascular disease, cognitive and mood disorders, and increased all-cause mortality. []
The American College of Obstetricians and Gynecologists (ACOG) recommends systemic hormone therapy for primary ovarian insufficiency when not contraindicated, generally continuing until the average age of natural menopause, around 50–51 years old. []
Related: 2 major misconceptions about menopause—from the experts, for the expertsHormone therapy is different when hormones are being replaced early
Dr. Emont emphasized that hormone therapy in this setting is not the same conversation clinicians often have with patients after natural menopause.
“This is actually truly hormone replacement therapy,” he said. “You are replacing the hormones that they are supposed to have at this point in their life.”
That does not mean treatment is automatic for every patient. Contraindications still matter. A history of hormone-sensitive cancer, thromboembolic risk, uterine status, migraine history, route of therapy, patient preferences, and the need for endometrial protection all need to be considered.
For many patients with iatrogenic early menopause, the goal is not only relief from hot flashes, night sweats, sleep disruption, genitourinary symptoms, and mood changes.
Protecting bone health, reducing downstream risk where possible, and restoring a hormonal environment closer to what the patient would have had without gonadotoxic treatment.
Survivorship care has to include ovarian failure
The case also highlights a familiar gap in cancer survivorship. Oncology teams may be focused on remission, recurrence risk, and treatment complications. Surgeons may be focused on the immediate consequences of oophorectomy. Primary care clinicians may inherit the issue years later without a clear survivorship plan. OB/GYNs may not see the patient until symptoms have gone untreated for years.
But premature menopause sits across all of those specialties.
If chemotherapy, transplant, pelvic radiation, ovarian surgery, or another intervention may impair ovarian function, the patient should be counseled before treatment when possible.
After treatment, amenorrhea, vasomotor symptoms, genitourinary symptoms, and confirmatory labs should trigger follow-up, not reassurance that symptoms may eventually fade.
Clinicians should document ovarian status, assess symptoms, review fertility implications when relevant, evaluate bone and cardiovascular risk, discuss sexual health, and either initiate appropriate therapy or refer promptly to someone who can.
The harm is not just hot flashes
One of Dr. Emont’s central frustrations was that the patient had spent 6 years without replacement hormones during what should have been peak reproductive hormone years.
That delay matters. The symptoms themselves can be debilitating, but the larger issue is that untreated early estrogen deficiency may affect multiple organ systems over time.
This is why “there’s not much to do” is such a consequential message; it tells the patient their symptoms are inevitable. It also misses a chance to reduce preventable risk.
A handoff cannot be the end of responsibility
Dr. Emont said the patient was started on hormone therapy the day he first saw her. “It’s better late than never,” he said, “but this conversation should have happened 6 years ago.”
For physicians, the takeaway is straightforward: When treatment causes early menopause, menopause management is part of the treatment. It should not depend on the patient finding the right clinician years later, after being told to wait out symptoms that were never benign.
Iatrogenic menopause is a foreseeable endocrine consequence of care—and it needs a care plan.
Related: 3 key factors for female longevity that docs aren’t talking about enough